| Literature DB >> 35010320 |
Ju-Mi Hwang1, Jeong-Won Bae1, Eun-Ju Jung2, Woo-Jin Lee1, Woo-Sung Kwon1,2.
Abstract
Although novaluron is an insect growth regulator with a low mammalian acute toxicity and a low risk to the environment and nontarget organisms, toxic effects of novaluron have been reported. However, no studies have yet evaluated the effect of novaluron on reproduction. Therefore, we examined the effects of novaluron on sperm functions. The spermatozoa of ICR mice were incubated with various concentrations of novaluron to induce capacitation. Then, sperm motion parameters and capacitation status were evaluated using CASA program and H33258/chlortetracycline staining. In addition, PKA activity and tyrosine phosphorylation were evaluated by Western blotting. After exposure, various sperm motion parameters were significantly decreased in a dose-dependent manner. The acrosome reaction was also significantly decreased in the high concentration groups. Sperm viability was significantly reduced at the highest concentration. In addition, PKA activity and tyrosine phosphorylation were also significantly altered. Thus, novaluron affects sperm viability, sperm motility, and motion kinematics during capacitation. Furthermore, it may promote the reduction in acrosome reactions. The physiological suppression of sperm function may depend on abnormal tyrosine phosphorylation via the alteration of PKA activity. Therefore, we suggest that it is necessary to consider reproductive toxicity when using novaluron as a pesticide.Entities:
Keywords: capacitation; novaluron; sperm function; spermatozoa
Mesh:
Substances:
Year: 2021 PMID: 35010320 PMCID: PMC8751217 DOI: 10.3390/ijerph19010061
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Effects of novaluron on sperm motility and motion kinematics.
| Concentration of Novaluron (µM) | |||||
|---|---|---|---|---|---|
| Control | 0.1 | 1 | 10 | 100 | |
| MOT (%) | 65.28 ± 1.89 a | 55.84 ± 1.70 a,b | 51.93 ± 2.61 b | 52.24 ± 1.74 b | 38.23 ± 4.49 c |
| Rapid (%) | 48.73 ± 2.13 a | 40.30 ± 1.60 a,b | 36.91 ± 1.97 b | 37.27 ± 2.99 b | 25.11 ± 3.61 c |
| Medium (%) | 16.36 ± 1.04 | 15.19 ± 0.53 | 14.64 ± 1.27 | 14.45 ± 1.68 | 12.90 ± 1.32 |
| Slow (%) | 0.17 ± 0.11 | 0.31 ± 0.10 | 0.38 ± 0.14 | 0.52 ± 0.24 | 0.14 ± 0.06 |
| Progressive (%) | 65.10 ± 1.84 a | 55.49 ± 1.62 a,b | 51.55 ± 2.61 b | 51.72 ± 1.67 b | 38.01 ± 4.42 c |
| VCL (μm/s) | 61.33 ± 3.00 a | 50.49 ± 2.53 a,b | 45.43 ± 1.54 b | 46.42 ± 4.06 b,c | 32.00 ± 4.10 c |
| VSL (μm/s) | 25.90 ± 2.93 a | 21.74 ± 1.85 a | 18.01 ± 1.74 a,b | 20.11 ± 1.88 a,b | 12.49 ± 1.98 b |
| VAP (μm/s) | 35.55 ± 2.69 a | 29.31 ± 2.03 a,b | 25.23 ± 1.68 a,b,c | 26.94 ± 2.38 b,c | 17.63 ± 2.66 c |
| BCF (Hz) | 4.71 ± 0.26 a | 3.78 ± 0.22 a,b | 3.48 ± 0.25 a,b,c | 3.61 ± 0.31 b,c | 2.52 ± 0.36 c |
| ALH (μm) | 2.40 ± 0.07 a | 1.94 ± 0.09 a,b | 1.83 ± 0.07 b | 1.79 ± 0.15 b | 1.30 ± 0.17 c |
Sperm motility and motion kinematics are presented as mean ± SEM, n = 9. Values with different superscript letters (a,b,c) indicate significant differences between the control and treatment groups (p < 0.05). MOT—sperm motility (%); Rapid—rapid sperm motility (%); Medium—medium sperm motility (%); Slow—slow sperm motility (%); Progressive—progressive sperm motility (%); VCL—curvilinear velocity (μm/s); VSL—straight-line velocity (μm/s); VAP—average path velocity (μm/s); BCF—beat cross frequency (Hz); ALH—mean amplitude of head lateral displacement (μm).
Figure 1Effects of novaluron on cell viability. Cell viability after exposure to different concentrations of novaluron. Data represent mean ± SEM, n = 4. Data were evaluated by one-way ANOVA and represent mean ± SEM, n = 4. Values with different superscripts (A,B) indicate significant differences between the control and treatment groups (p < 0.05).
Figure 2Effects of novaluron on capacitation status. (A) Patterns of live and acrosome-reacted sperms (AR pattern). (B) Patterns of live and capacitated sperms (B pattern). (C) Patterns of live and non-capacitated sperms (F pattern). Data were quantified by one-way ANOVA and represent mean ± SEM, n = 4. Values with different superscript letters (A,B,C) indicate significant differences between the control and treatment groups (p < 0.05).
Figure 3Effect of novaluron on PKA activity and protein tyrosine phosphorylation. (A) Phospho-PKA substrate density was measured at approximately 120, 55, 30, and 20 kDa. (B) Phospho-PKA substrates were probed. Lane 1: control; Lane 2: 0.1 µM novaluron; Lane 3: 1 µM novaluron; Lane 3: 10 µM novaluron; Lane 5: 100 µM novaluron. (C) The density of phosphotyrosine protein substrates was measured at approximately 100, 60, and 22 kDa. (D) Phosphotyrosine protein substrates were probed. Lane 1: control; Lane 2: 0.1 µM novaluron; Lane 3: 1 µM novaluron; Lane 4: 10 µM novaluron; Lane 5: 100 µM novaluron. Data were evaluated by one-way ANOVA and represent mean ± SEM, n = 4. Values with different superscripts (A,B,C,a,b,I,II,III,i,ii) indicate significant differences between the control and treatment groups (p < 0.05).